These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22639786)

  • 1. Tertiary prophylaxis in adults: is there a rationale?
    Gringeri A; Lambert T; Street A; Aledort L;
    Haemophilia; 2012 Sep; 18(5):722-8. PubMed ID: 22639786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis in people with haemophilia.
    Coppola A; Franchini M; Tagliaferri A
    Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis in adults with haemophilia.
    Hay CR
    Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis in the haemophilia population-optimizing therapy.
    Carcao MD; Aledort LM;
    Haemophilia; 2007 May; 13(3):227-32. PubMed ID: 17498070
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
    Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
    Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison between prophylaxis and on demand treatment for severe haemophilia.
    Khoriaty R; Taher A; Inati A; Lee C
    Clin Lab Haematol; 2005 Oct; 27(5):320-3. PubMed ID: 16178913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    J Intern Med; 1998 Dec; 244(6):515-22. PubMed ID: 9893105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying and overcoming barriers to prophylaxis in the management of haemophilia.
    Petrini P
    Haemophilia; 2007 Sep; 13 Suppl 2():16-22. PubMed ID: 17685919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemophilia prophylaxis: how can we justify the costs?
    Feldman BM; Berger K; Bohn R; Carcao M; Fischer K; Gringeri A; Hoots K; Mantovani L; Willan AR; Schramm W
    Haemophilia; 2012 Sep; 18(5):680-4. PubMed ID: 22507524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    Pharmacoeconomics; 2002; 20(11):759-74. PubMed ID: 12201795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
    Khawaji M; Astermark J; Berntorp E
    Eur J Haematol; 2012 Apr; 88(4):329-35. PubMed ID: 22221195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
    Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
    Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemophilia care in Europe: the ESCHQoL study.
    Schramm W; Gringeri A; Ljung R; Berger K; Crispin A; Bullinger M; Giangrande PL; Von Mackensen S; Mantovani LG; Nemes L; Serban M;
    Haemophilia; 2012 Sep; 18(5):729-37. PubMed ID: 22639833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary.
    Petrini P; Chambost H; Nemes L
    Haemophilia; 2004 Oct; 10 Suppl 4():94-6. PubMed ID: 15479379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.